Proton pump inhibitors relieve and prevent symptoms related to gastric acidity after esophagectomy

被引:22
作者
Okuyama, Manabu [1 ]
Motoyama, Satoru [1 ]
Maruyama, Kiyotomi [1 ]
Sasaki, Kenji [1 ]
Sato, Yusuke [1 ]
Ogawa, Jun-ichi [1 ]
机构
[1] Akita Univ, Sch Med, Dept Surg, Akita 0108543, Japan
关键词
D O I
10.1007/s00268-007-9325-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Denervated stomach used as an esophageal substitute after esophagectomy often retains or spontaneously recovers acid production. The aims of the present study were to assess the relationship between esophageal acid exposure or gastric acidity and reflux-related symptoms after esophagectomy, and to assess the ability of proton pump inhibitors (PPIs) to relieve gastroesophageal reflux-related symptoms. Methods Forty-four patients underwent esophageal and gastric 24-h pH monitoring early after esophagectomy with gastric reconstruction. Initially, patients with both gastric acidity and reflux symptoms were treated with PPIs (Treatment group), then all patients with gastric acidity, whether symptomatic or not, were treated (Prevention group). Reflux-related symptoms were correlated with esophageal acid exposure and postoperative gastric acidity. Gastric acidity was then correlated with serum anti-Helicobacter pylori immunoglobulin G (IgG) titers and preoperative endoscopic findings Results Sixteen patients (36.4%) reporting reflux and showing gastric acid production were treated with PPIs, which provided relief to 13 (81.3%). Although symptoms did not correlate with the esophageal acid exposure, postoperative gastric acidity was significantly greater among patients who were symptomatic than among those who were not. Overall, acid production was lower in older patients (> 64 years of age), although older patients who were H. pylori-negative and without chronic atrophic gastritis also showed high levels of gastric acidity. Conclusions Proton pump inhibitors should be administered prophylactically early after esophagectomy to relieve and prevent reflux-related symptoms. Candidates for preventive therapy include those less than 64 years of age or older patients who are H. pylori-negative and without chronic atrophic gastritis.
引用
收藏
页码:246 / 254
页数:9
相关论文
共 32 条
[1]   The prevalence of Helicobacter Pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan [J].
Abe, Y ;
Ohara, S ;
Koike, T ;
Sekine, H ;
Iijima, K ;
Kawamura, M ;
Imatani, A ;
Kato, K ;
Shimosegawa, T .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (07) :1213-1221
[2]   Analysis of results of surgery performed over a 20-year period on 500 patients with cancer of the thoracic esophagus [J].
Abo, S ;
Kitamura, M ;
Hashimoto, M ;
Izumi, K ;
Minamiya, Y ;
Shikama, T ;
Suzuki, H ;
Temma, K ;
Kamata, S ;
Saito, R .
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1996, 26 (02) :77-82
[3]   Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years [J].
Ando, N ;
Ozawa, S ;
Kitagawa, Y ;
Shinozawa, Y ;
Kitajima, M .
ANNALS OF SURGERY, 2000, 232 (02) :225-232
[4]   Comparison of stapled and hand-sewn esophagogastric anastomoses [J].
Beitler, AL ;
Urschel, JD .
AMERICAN JOURNAL OF SURGERY, 1998, 175 (04) :337-340
[5]  
Blazeby JM, 2000, CANCER, V88, P1781
[6]   Human model of duodenogastro-oesophageal reflux in the development of Barrett's metaplasia [J].
Dresner, SM ;
Griffin, SM ;
Wayman, J ;
Bennett, MK ;
Hayes, N ;
Raimes, SA .
BRITISH JOURNAL OF SURGERY, 2003, 90 (09) :1120-1128
[7]   Associations between different forms of gastro-oesophageal reflux disease [J].
ElSerag, HB ;
Sonnenberg, A .
GUT, 1997, 41 (05) :594-599
[8]   Effects of aging and gastritis on gastric acid and pepsin secretion in humans: A prospective study [J].
Feldman, M ;
Cryer, B ;
McArthur, KE ;
Huet, BA ;
Lee, E .
GASTROENTEROLOGY, 1996, 110 (04) :1043-1052
[9]   Evaluation and management of laryngopharyngeal reflux [J].
Ford, CN .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (12) :1534-1540
[10]  
Grade A, 1997, AM J GASTROENTEROL, V92, P2040